Skip to main content
Clinical Trials/NL-OMON27467
NL-OMON27467
Completed
Not Applicable

Observational study;<br>Bevacizumab, Radiotherapy and Temozolomide Safety study in biopsied or resected primary GBM patients.

Departments of Neurosurgery, Radiation Oncology, Clinical Oncology and NeurologyAcademisch Medisch CentrumMeibergdreef 151105 AZ Amsterdam+31 20 56691110 sites20 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
1. Primary Glioblastoma Multiforme (NLD: primair Glioblastoma multiforme),
Sponsor
Departments of Neurosurgery, Radiation Oncology, Clinical Oncology and NeurologyAcademisch Medisch CentrumMeibergdreef 151105 AZ Amsterdam+31 20 5669111
Enrollment
20
Status
Completed
Last Updated
last year

Overview

Brief Summary

/A

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
Departments of Neurosurgery, Radiation Oncology, Clinical Oncology and NeurologyAcademisch Medisch CentrumMeibergdreef 151105 AZ Amsterdam+31 20 5669111

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with histologically proven GBM (biopsy or resection);
  • 2\. Can start 3\-8 weeks post biopsy or surgery;

Exclusion Criteria

  • 1\. Age \<18 years;
  • 2\. Pregnancy;

Outcomes

Primary Outcomes

Not specified

Similar Trials